91
Participants
Start Date
December 22, 2015
Primary Completion Date
April 11, 2018
Study Completion Date
May 8, 2020
Atezolizumab
Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
Bendamustine
Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m\^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
Cyclophosphamide
Cyclophosphamide will be administered at a dose of 750 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Doxorubicin
Doxorubicin will be administered at a dose of 50 mg/m\^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
Obinutuzumab
Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
Prednisone
Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m\^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
Vincristine
Vincristine will be administered at a dose of 1.4 mg/m\^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
Rituximab
Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m\^2 IV on Day 1 of Cycle 1-8, during induction treatment.
Concord Repatriation General Hospital; Haematology, Sydney
Calvary Mater Newcastle, Waratah
Austin Hospital, Heidelberg
Monash Medical Centre, Clayton
The Queen Elizabeth Hospital; Haematology/Oncology, Woodville South
New York Uni Medical Center, New York
Memorial Sloan-Kettering Cancer Center, New York
AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette, Torino
Western Pennsylvania Hospital, Pittsburgh
Georgetown University Medical Center, Washington D.C.
Asst Papa Giovanni XXIII, Bergamo
University Miami, Miami
Azienda Ospedaliera S. Orsola-Malpighi, Bologna
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola
Ospedale Infermi di Rimini, Rimini
Az. Osp. S. Maria Delle Croci; U.O. Di Ematologia, Ravenna
Azienda Ospedaliera Univ, Florence
Texas Oncology-Tyler, Irving
Texas Oncology, Austin
Rocky Mountain Cancer Center - Aurora, Aurora
Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield
Hoffmann-La Roche
INDUSTRY